We showed that GLT1D1 was significantly upregulated in incurable lymphoma (MCL) and in a subset of DLBCL patients with poor prognosis, suggesting that high expression of GLT1D1 may predict high risk of lymphoma relapse, likely due in part to immunosuppression. Here, GLT1D1 is linked to mantle cell lymphoma.